Cencora operates as a pharmaceutical distributor and healthcare services provider, sourcing and distributing prescription medications, over-the-counter products, vaccines, specialty pharmaceuticals, and medical supplies across the United States and internationally. The company serves acute care hospitals, health systems, retail and mail order pharmacies, long-term care facilities, medical clinics, and veterinary markets. Beyond distribution, Cencora provides pharmacy management and staffing services, supply management software, packaging solutions, clinical trial support, data analytics, and sales force services to manufacturers and healthcare providers.
The U.S. Healthcare Solutions segment represents the company's primary revenue driver, encompassing distribution of generic and injectable pharmaceuticals, plasma and blood products, vaccines, and specialty drugs. This segment also includes animal health products for companion and production animals. The company offers consulting services focused on pharmacy management and outcomes research for pharmaceutical and biotechnology clients, along with commercialization support services.
The International Healthcare Solutions segment provides pharmaceutical wholesale distribution and related services across multiple markets, including pharmacies, hospitals, and health centers. This segment also operates specialty transportation and logistics services for the biopharmaceutical industry. With approximately 47,000 full-time employees, Cencora operates at substantial scale within healthcare distribution. The company was founded in 1871 and rebranded from AmerisourceBergen Corporation to Cencora in August 2023.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $7.96 | $8.02 | +5.7% | |
| 2024 | $7.53 | $7.60 | -11.7% | |
| 2023 | $8.53 | $8.62 | +6.1% | |
| 2022 | $8.04 | $8.15 | +8.8% | |
| 2021 | $7.39 | $7.48 | +131.1% | |
| 2020 | $-23.74 | $-23.74 | -3868.3% | |
| 2019 | $0.63 | $0.64 | -41.1% | |
| 2018 | $1.07 | $1.08 | +167.7% | |
| 2017 | $-1.58 | $-1.58 | -346.9% | |
| 2016 | $0.64 | $0.66 | -59.0% | |
| 2015 | $1.56 | $1.72 | +437.9% | |
| 2014 | $0.29 | $0.30 | +31.8% | |
| 2013 | $0.22 | $0.22 | -66.7% | |
| 2012 | $0.66 | $0.67 | +22.2% | |
| 2011 | $0.54 | $0.55 | +8.0% | |
| 2010 | $0.50 | $0.51 | -69.9% | |
| 2009 | $1.66 | $1.67 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-09-30 | 2025-11-25 | 0001140859-25-000131 | SEC ↗ |
| 2024-09-30 | 2024-11-26 | 0001140859-24-000177 | SEC ↗ |
| 2023-09-30 | 2023-11-21 | 0001140859-23-000197 | SEC ↗ |
| 2022-09-30 | 2022-11-22 | 0001140859-22-000098 | SEC ↗ |
| 2021-09-30 | 2021-11-23 | 0001140859-21-000058 | SEC ↗ |
| 2020-09-30 | 2020-11-19 | 0001140859-20-000050 | SEC ↗ |
| 2019-09-30 | 2019-11-19 | 0001140859-19-000040 | SEC ↗ |
| 2018-09-30 | 2018-11-20 | 0001140859-18-000053 | SEC ↗ |